Breast cancer prognosis marker and application

Abstract

The invention discloses a breast cancer prognosis evaluating marker and application, and belongs to the technical field of biology. The invention aims to find a marker for effectively evaluating breast cancer prognosis. TCGA, GEO and DNA methylation data of the whole genome level autonomously generated based on a sequencing technology are integrated, it is revealed that the tumor center is in a hypoxic state compared with the tumor edge, survival analysis finds that the HR of a CpG site cg15190451 is smaller than 1, it shows that the breast cancer progress risk is reduced along with increase of the methylation level, and the higher the level is, the patient prognosis is better; and it is prompted that the breast cancer prognosis effect can be judged according to the methylation level of the gene SLC16A5 where cg15190451 is located. The breast cancer prognostic marker is obtained by verifying hypoxia markers in an HER2 positive breast cancer sample on the basis of the expression level of SLC16A5, the breast cancer prognostic evaluation efficiency can be improved, the cost is saved, and the marker is suitable for popularization and application and has a good application prospect.

Description

technical field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a prognostic marker and application of breast cancer. Background technique

[0002] In the United States, 12 percent of women will be diagnosed with breast cancer in their lifetime, and more than 250,000 new breast cancer cases were diagnosed in the United States in 2017. Breast cancer can be divided into 3 main subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly known as HER2): Hormone receptor positive / ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), triple negative (tumor lacks all 3 standard molecular markers; 15%). More than 90% of breast cancers are not metastatic at the time of diagnosis. For patients without metastatic disease, the goals of treatment are tumor eradication and prevention of recurrence. Triple-negative breast cancer is more likely to ...

Images